Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2014 2
2015 5
2016 4
2017 2
2018 7
2019 5
2020 3
2021 8
2022 5
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ. Walker BA, et al. Among authors: szalat r. Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8. Blood. 2018. PMID: 29884741 Free PMC article.
Diagnosis of Castleman Disease.
Szalat R, Munshi NC. Szalat R, et al. Hematol Oncol Clin North Am. 2018 Feb;32(1):53-64. doi: 10.1016/j.hoc.2017.09.005. Hematol Oncol Clin North Am. 2018. PMID: 29157619 Review.
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC. Samur MK, et al. Among authors: szalat r. Blood. 2023 Apr 6;141(14):1724-1736. doi: 10.1182/blood.2022017094. Blood. 2023. PMID: 36603186 Free PMC article.
Genomic Instability in Multiple Myeloma.
Alagpulinsa DA, Szalat RE, Poznansky MC, Shmookler Reis RJ. Alagpulinsa DA, et al. Among authors: szalat re. Trends Cancer. 2020 Oct;6(10):858-873. doi: 10.1016/j.trecan.2020.05.006. Epub 2020 May 30. Trends Cancer. 2020. PMID: 32487486 Review.
Novel Agents in Multiple Myeloma.
Szalat R, Munshi NC. Szalat R, et al. Cancer J. 2019 Jan/Feb;25(1):45-53. doi: 10.1097/PPO.0000000000000355. Cancer J. 2019. PMID: 30694859 Free PMC article. Review.
Deciphering racial disparities in multiple myeloma outcomes.
Bertrand KA, Szalat R. Bertrand KA, et al. Among authors: szalat r. Blood Adv. 2024 Jan 9;8(1):234-235. doi: 10.1182/bloodadvances.2023011457. Blood Adv. 2024. PMID: 38194241 Free PMC article. No abstract available.
Genomic heterogeneity in multiple myeloma.
Szalat R, Munshi NC. Szalat R, et al. Curr Opin Genet Dev. 2015 Feb;30:56-65. doi: 10.1016/j.gde.2015.03.008. Epub 2015 May 16. Curr Opin Genet Dev. 2015. PMID: 25982873 Review.
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.
Muchtar E, Dispenzieri A, Wisniowski B, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Geyer SM, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Witteles R, Sanchorawala V, Szalat R, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Wechalekar A, Gertz MA. Muchtar E, et al. Among authors: szalat r. J Clin Oncol. 2023 Mar 1;41(7):1393-1403. doi: 10.1200/JCO.22.00643. Epub 2022 Oct 10. J Clin Oncol. 2023. PMID: 36215675 Free PMC article.
44 results